Harmony Biosciences Eyes Blockbuster Future After Record Year

Harmony Biosciences Holdings, Inc. ((HRMY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Harmony Biosciences’ latest earnings call struck an optimistic tone, underscored by record revenues, sustained patient growth, and a reaffirmed path to blockbuster status for WAKIX in 2026. Management acknowledged rising expenses, IP overhang, and competitive pressures, but argued that a strong balance sheet and a rich late-stage pipeline leave the company well positioned for long-term value creation.

Record Revenue Performance in Q4 and Full-Year 2025

Harmony delivered Q4 2025 net product revenue of $243.8 million, up 21% from $201.3 million in the prior-year quarter and the highest in the company’s history. Full-year 2025 WAKIX revenue reached $868.5 million, reflecting sustained commercial execution and growing market penetration in narcolepsy.

Sustained Patient Growth Supports Long Runway

The company reported its third straight quarter with roughly 400 or more average patient adds, a first for the WAKIX franchise. Average patients on therapy reached about 8,500, leaving significant remaining headroom within an estimated 80,000 diagnosed narcolepsy patients in the U.S. market.

Reiterated Blockbuster WAKIX Guidance for 2026

Harmony reiterated its outlook for WAKIX net revenue between $1.0 billion and $1.04 billion in 2026, framing this as the franchise’s first move into blockbuster territory. Management linked this confidence to recent volume trends, label expansion, and continued commercial investments intended to deepen penetration and improve conversion.

Robust Cash Generation and Fortified Balance Sheet

In 2025, Harmony generated $348.2 million in cash from operations, underscoring the underlying profitability of the WAKIX franchise despite heavier spending. The company ended Q4 with $882.5 million in cash, cash equivalents, and investments, giving it ample flexibility to fund its pipeline and pursue business development opportunities.

Pipeline Momentum and Multiple Late-Stage Catalysts

Harmony is running five Phase III registrational trials across central nervous system indications, positioning the company for several high-impact readouts over the next two years. Key milestones include a planned NDA for pitolisant GR in Q2 2026, expected top-line data for pitolisant HD and EPX-100 in 2027, and Phase I pharmacokinetic results for orexin-2 agonist BP1.15205 by mid-2026.

Label Expansion into Pediatric Cataplexy

The FDA approved WAKIX on February 13, 2026, for treating cataplexy in patients six years and older, opening access to the pediatric narcolepsy segment. Management emphasized that this expansion not only adds a new growth vector but also advances Harmony’s pursuit of pediatric exclusivity, which would extend regulatory protection for WAKIX.

Progress and Remaining Risk in IP and ANDA Litigation

Harmony has reached settlements with six of seven ANDA filers, which would push potential generic entry to no earlier than March 2030 if pediatric exclusivity is granted. One filer remains unresolved and a recent trial decision is pending, leaving some residual uncertainty around the timing of generic competition, particularly if exclusivity is not ultimately secured.

Encouraging Efficacy Signals from EPX-100 in Epilepsy

Interim data from EPX-100 label-extension and open-label extension studies showed median seizure reductions of about 50%, with roughly half of patients achieving at least a 50% reduction after six months or more of exposure. The drug was generally well tolerated without new monitoring requirements, bolstering its potential as a differentiated epilepsy asset heading into Phase III.

Commercial Expansion and Process Improvements

Harmony is scaling its commercial footprint, expanding field-based headcount by around 20% across sales, reimbursement, and remote teams to support deeper market reach. The company is also rolling out a new patient portal and other process enhancements aimed at shortening time to dispense and improving conversion from prescription to on-therapy status.

Pressure on Non-GAAP Earnings Despite Growth

Non-GAAP adjusted net income in Q4 fell to $33.4 million, or $0.57 per diluted share, down roughly 48% from $64.2 million, or $1.10, in the prior-year period. Management attributed this earnings compression primarily to higher R&D costs, stepped-up commercialization spending, and legal expenses tied to ANDA settlements and IP defense.

Sharp Rise in Operating Expenses

Total operating expenses in Q4 climbed to $136.7 million, up from $91.1 million a year earlier, an increase of about 45%. The company framed this as deliberate investment to support its expanding late-stage pipeline, broader commercial infrastructure, and ongoing litigation efforts necessary to protect the WAKIX franchise.

Litigation Overhang and Generic Timing Uncertainty

Despite meaningful IP progress, Harmony acknowledged ongoing uncertainty around its remaining ANDA case and the timing of the court’s decision and any appeals. If pediatric exclusivity is not granted, the company flagged September 2029 as a potential earlier generic entry date, a risk investors will need to monitor against the backdrop of current growth.

Enrollment and Competitive Headwinds in Key Programs

Management noted enrollment pressure in its pitolisant HD Phase III narcolepsy and idiopathic hypersomnia studies, reflecting a crowded trial environment in sleep and wakefulness disorders. The presence of multiple orexin-2 agonists in development, including a leading program already at NDA stage, could influence competitive positioning and timelines for Harmony’s own candidate.

Seasonal Q1 Dynamics Likely to Weigh on Near-Term Results

Harmony guided to typical industry seasonality in Q1 2026, including higher gross-to-net deductions as insurance benefits reset and patients face higher co-pays. The company also pointed to a possible drawdown in trade inventory, which could skew revenue phasing even as underlying demand trends remain healthy.

Elevated R&D Spend to Sustain Pipeline Ambitions

Looking ahead, Harmony plans a significant ramp in R&D spending through 2026 to support its five ongoing registrational Phase III programs and a potential sixth. While this will keep operating expenses elevated in the near term, management views these investments as critical to diversifying revenue beyond WAKIX and driving long-term growth.

Forward-Looking Guidance and Strategic Outlook

Management reiterated 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion, anchored by record 2025 revenue and three consecutive quarters of strong patient adds. With nearly $900 million in cash, substantial operating cash flow, and multiple Phase III and regulatory catalysts approaching, Harmony expects to balance aggressive pipeline investment with disciplined financial management, while navigating seasonal, litigation, and competitive headwinds.

Harmony’s earnings call painted a picture of a company trading near-term earnings leverage for scale, pipeline depth, and prolonged exclusivity for WAKIX. For investors, the story now hinges on sustained patient growth, execution on late-stage programs, and successful defense of intellectual property, all of which could justify the company’s push toward durable blockbuster status.